Pseudovirus News and Research

RSS

Cross-reactive coronavirus antibodies might not be cross-neutralizing

In a recent study posted to Research Square* preprint server, researchers reported that cross-reactive antibodies against coronaviruses (CoVs) might not cross-neutralize all CoVs.

25 Apr 2022

Antibodies that neutralize most sarbecoviruses, including SARS-CoV-2 variants

Researchers isolate three mAbs that broadly neutralized sarbecoviruses and carried out virological and structural studies of these mAbs.

21 Apr 2022

Hybrid alphavirus-SARS-CoV-2 pseudovirus system rapidly measures neutralizing antibodies

Do a person's antibodies work to block the COVID-19 virus from infecting one's system? Are these antibodies also capable of blocking emerging variants such as the omicrons?

21 Apr 2022

New research on immune correlates for Janssen Ad26.Cov2.S COVID vaccine

ENSEMBLE data was used to evaluate three immune markers as correlates of protection following a single dose of Ad26.COV2.S vaccine.

18 Apr 2022

Study identifies Etravirine and Dolutegravir as effective entry inhibitors of wild-type and predominant variants of SARS-CoV-2

Researchers identified drugs inhibiting the entry of SARS-CoV-2.

18 Apr 2022

Monoclonal antibodies from COVID-19 convalescent donors target conserved site

Researchers found six monoclonal antibodies binding to the spike proteins of all human coronaviruses.

18 Apr 2022

Durable neutralizing response against Omicron after heterologous vaccine boosting

Researchers assess the impact of homologous and heterologous primary-booster vaccine dose combinations.

15 Apr 2022

S-Nitrosylation of ACE2 inhibits binding of SARS-CoV-2 spike protein

In a recent study posted to the bioRxiv* preprint server, researchers developed aminoadamantane nitrates compounds that inhibit the ion channels formed by the envelope (E) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and enable targeted drug delivery of nitric oxide (NO)-related group for S-nitrosylation of host angiotensin-converting enzyme 2 (ACE2), which would inhibit ACE2 binding with the viral spike (S) protein and thereby inhibit viral replication in the host.

11 Apr 2022

Study explores the antibody evasion pattern of SARS-CoV-2 Omicron sublineages

...

8 Apr 2022

SARS-CoV-2 spike S375F mutation triggered the explosive spread of Omicron

In a recent study posted to the bioRxiv* preprint server, researchers investigated the mutation in the viral spike (S) protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.1 variant (referred to as Omicron in the present study) that is responsible for the variant’s virological features.

7 Apr 2022

COVID boosters protect you better than monoclonal antibodies, or natural infection

In a new study published in the journal Science Translational Medicine, researchers analyzed the neutralization of the Omicron BA.1 variant pseudovirus by post-vaccination serum samples.

6 Apr 2022

Study shows circular RNA vaccine provides robust protection against SARS-CoV-2 in mice and rhesus macaques

Researchers investigated the effectiveness of a circRNA vaccine against SARS-CoV-2 and its Delta and Omicron variants, which elicited significant antibody and T-cell responses in mice and rhesus macaques.

6 Apr 2022

SARS-CoV-2 Omicron breakthrough infections induce antibodies with cross-variant neutralization potential and recall memory B cells

Researchers reported breakthrough infections by SARS-CoV-2’s new variant of concern, Omicron, that elicited broadly cross-reactive neutralizing antibodies in the BNT162b2-vaccinated individuals.

5 Apr 2022

Pseudovirus News and Research

Cross-reactive coronavirus antibodies might not be cross-neutralizing

Antibodies that neutralize most sarbecoviruses, including SARS-CoV-2 variants

Hybrid alphavirus-SARS-CoV-2 pseudovirus system rapidly measures neutralizing antibodies

New research on immune correlates for Janssen Ad26.Cov2.S COVID vaccine

Study identifies Etravirine and Dolutegravir as effective entry inhibitors of wild-type and predominant variants of SARS-CoV-2

Monoclonal antibodies from COVID-19 convalescent donors target conserved site

Durable neutralizing response against Omicron after heterologous vaccine boosting

S-Nitrosylation of ACE2 inhibits binding of SARS-CoV-2 spike protein

Study explores the antibody evasion pattern of SARS-CoV-2 Omicron sublineages

SARS-CoV-2 spike S375F mutation triggered the explosive spread of Omicron

COVID boosters protect you better than monoclonal antibodies, or natural infection

Study shows circular RNA vaccine provides robust protection against SARS-CoV-2 in mice and rhesus macaques

SARS-CoV-2 Omicron breakthrough infections induce antibodies with cross-variant neutralization potential and recall memory B cells

Pre-existing memory B cell dynamics during SARS-CoV-2 Omicron breakthrough infection

Messenger ribonucleic acid boosters shown to be effective against Omicron infections in mice

Study investigates room-temperature stable, self-amplifying RNA vaccine against SARS-CoV-2

Evusheld™ found to poorly neutralize Omicron in kidney transplant patients

Breast milk components show potent in vitro SARS-CoV-2 inhibition

UB-612 vaccine booster found to elicit high neutralizing antibody levels against SARS-CoV-2 Omicron

Study evaluates humoral and cellular immune memory induced by different COVID-19 vaccines

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News